Topadur Pharma AG (Schlieren, Zurich) is a clinical-stage biotech company developing small-molecule therapies that target impaired microcirculation and tissue regeneration. Its proprietary DualTOP® platform combines complementary pharmacological activities in single molecules for local use.
Products, services, technology
The lead compound TOP-N53 is in a Phase 2a study for digital ulcers in systemic sclerosis and has orphan designation in the US and the EU. TOP-M119 for alopecia, co-developed with Oshen Holdings, is in IND-enabling studies.
Cooperation possibilities
Topadur welcomes partnering discussions.
- https://www.topadur.com
- +41 44 755 44 66
- Send an email
- Matthias Schäfer